NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. Interim ...

Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/ ...

Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL ...

Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues ...

U rinary albumin-creatinine ratio (UACR) may be slightly better than urinary protein-creatinine ratio (UPCR) at predicting ...

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that it will have an oral and a poster presentation at the ...

In an interview with " Fox & Friends" last week, HHS Secretary Robert F. Kennedy Jr. lauded cell phone restrictions in schools, pointing to links between social media use and anxiety and depression.

Two police officers have moved into the prison cell next door to former French president Nicolas Sarkozy after he received death threats, it emerged today. The 70-year-old is said to have spent a ...